Trial Profile
Study of tofacitinib (TOF) in a case series of refractory rapidly progressive interstitial lung disease (ILD) associated with anti-melanoma differentiation-associated 5 gene (MDA5) antibody-positive (Ab+) dermatomyositis (DM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2018
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- 03 Aug 2018 New trial record
- 27 Jul 2018 Results (n=5) published in the Rheumatology